Social and economic burden of breast cancer in the North East region of Bulgaria

References

• Dimitrova M, Lakic D, Petrova G, et al. Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries. SAGE Open Med. 2020 May 20;8: 2050312120922029. PMID: 32547747; PMCID: PMC7249592 https://journals.sagepub.com/doi/full/10.1177/2050312120922029
   Web of Science ®Google Scholar
• Breast cancer: prevention and control; World Health Organization (accessed in Dec 2020) https://www.who.int/health-topics/cancer#tab=tab_1
   Google Scholar
• Breast cancer statistics; World Cancer Research Fund (accessed in Dec 2020) https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics
   Google Scholar
• Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the World. Asian Pac J Cancer Prev. 2016;17(sup3):43–46. PMID: 27165206 https://pubmed.ncbi.nlm.nih.gov/27165206/
   PubMedGoogle Scholar
• Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–e1037. PMID: 32710860 https://www.sciencedirect.com/science/article/pii/S2214109X20302151
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of et al. Cancer incidence and mortality worldwide patterns in Europe: estimates for 3640 countries and 25 major cancers in 185 countries. CA Cancer 2018. Eur J Clin. 2018 Nov;68(6):394–424. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.
   Google Scholar
• Cancer statistics - specific cancers; EUROSTAT 2020. [cited Jan 2021]. Available from: https://ec.europa.eu/eurostat/statistics-explained/pdfscache/39738.pdf
   Google Scholar
• OECD State of Health in the EU Bulgaria Country Health Profile 2017. [cited Jan 2021]. Available from: https://ec.europa.eu/health/sites/health/files/state/docs/chp_bulgaria_english.pdf
   Google Scholar
• National Statistical Institute. Official report, 2017. [cited Jan 2021]. Available from: http://www.nsi.bg/sites/default/files/files/publications/Zdraveopazvane_2017.pdf
   Google Scholar
• Valerianova Z, Atanasov T, Vukov M Cancer Incidence in Bulgaria, 2014 and 2015 Bulgarian National Cancer Registry 2014;XXV
   Google Scholar
• Trentham-Dietz A, Sprague BL, Klein R, et al. Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat. 2008;109(2):379–387.
   PubMed Web of Science ®Google Scholar
• Sharma N, Purkayastha A. Factors affecting quality of life in breast cancer patients: A descriptive and cross-sectional study with review of literature. J Midlife Health. 2017;8(2):75–83.
   PubMedGoogle Scholar
• Mokhatri-Hesari P. Montazeri A Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes. 2020;18(338). DOI:https://doi.org/10.1186/s12955-020-01591-x
   Google Scholar
• Imai H, Kuroi K, Ohsumi S, et al. Economic evaluation of the prevention and treatment of breast cancer-present status and open issues. Breast Cancer. 2007;14(1):81–87.
   PubMedGoogle Scholar
• JM A. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care. 2010 Sep;16(9):697–704. PMID: 20873957: https://www.ajmc.com/view/ajrmc_10sep_allen697to704
   PubMed Web of Science ®Google Scholar
• Alexandre RF, Santana CF, Hb S. Social and economic impact of patients with metastatic breast cancer in brazil. Value Health. 2018;21(1):S26. https://www.valueinhealthjournal.com/article/S1098-3015(18)30461-3/fulltext
   Google Scholar
• Pallis A, Tsiantou V, Simou E, et al. Pharmacoeconomic considerations in the treatment of breast cancer. Clinicoecon Outcomes Res. 2010;22:4747–6161.
   Google Scholar
• GLOBAL BURDEN OF DISEASE 2004 UPDATE: DISABILITY WEIGHTS FOR DISEASES AND CONDITIONS. WHO. [cited Jan 2021]. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf?ua=1
   Google Scholar
• Valerianova Z, Dimitrova N, Tonev VМ. Cancer Incidence in Bulgaria, 2014 and 2015, Volume XXV, Bulgarian National Cancer Registry, Sofia. 2017. Paradigma. ISSN: 1314-7315
   Google Scholar
• Cancer Incidence in Bulgaria, 2014 & 2015 2017;XXV. [cited Jan 2021]. Available from:https://www.sbaloncology.bg
   Google Scholar
• Deaths BA. DALY and other related measures of breast cancer in Yemeni women: findings of the global burden of disease study (1990–2010). J Cancer Res Pract. 2017;4(1):14–18.
   Google Scholar
• Bulgarian National Cancer Registry. 1952-present. [cited Jan 2021]. Available from: http://www.sbaloncology.bg/bg/bulgarian-cancer-registry.html
   Google Scholar
• Pharmacotherapeutic guidelines for oncology diseases in Bulgaria 2019; [cited Jan 2021]. Available from: https://www.ncpr.bg/images/Naredbi_za_priemane_na_FTR/29.10.2019/Naredba_11_ot_2019_FTR_med_onkologia_priturka.pdf
   Google Scholar
• Wittayanukorn S, Qian J, Westrick SC, et al. Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians’ offices and hospital outpatient departments. Res Social Adm Pharm. 2015 Sep-Oct;11(5):708–720. Epub 2014 Dec 18. PMID: 25582892.
   PubMed Web of Science ®Google Scholar
• Soerjomataram I, Lortet-Tieulent J, Ferlay J, et al. Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer. BMC Med Res Methodol. 2012;12(1):125.
   PubMedGoogle Scholar
• Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of disease study 2017. J Hematol Oncol. 2019;12(1):140.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J. Disability-adjusted life-years (dalys) for breast cancer and risk factors in 195 countries: findings from global burden of disease study 2017. medRxiv. 2020 April 02; 20050534. DOI:https://doi.org/10.1101/2020.04.02.20050534.
   Google Scholar
• European Cancer Information System, European Commission 2018 Available from: cancer burden statistics and trends across Europe | ECIS (europa.eu)
   Google Scholar
• GBD PROFILE: BULGARIA Institute for Health Metrics and Evaluation. [cited Jan 2021]. Available from:https://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_bulgaria.pdf
   Google Scholar
• Giuliani J, Bonetti A. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020 Sep;26(6):1486–1491. Epub 2020 Jun 23. PMID: 32576084.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Palbociclib or ribociclib in first-line treatment in patients with hormone receptor-positive/human epidermal receptor 2-negative advanced or metastatic breast cancer? a perspective based on pharmacologic costs. Clin Breast Cancer. 2019 Aug;19(4):e519–e521. Epub 2019 Feb 16. PMID: 30858036.
   PubMed Web of Science ®Google Scholar